This trial will first assess the effects of green cardamom (Elettaria cardamomum) on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1 and irisin in overweight or obese patients with nonalcoholic fatty liver disease (NAFLD). The gene discussed is FNDC5; the disease is metabolic dysfunction-associated steatotic liver disease.